Corrigendum to: Expression of HE4 in Endometrial Cancer and Its Clinical Significance (BioMed Research International (2015) 2015 (437468) DOI: 10.1155/2015/437468);Expression of HE4 in Endometrial Cancer and Its Clinical Significance

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Li, Xiao ^a   Gao, Yiping ^a   Tan, Mingzi ^a   Zhuang, Huiyu ^a   Gao, Jian ^a   Hu, Zhenhua ^a   Wang, Huimin ^a   Zhu, Liancheng ^a   Liu, Juanjuan ^a   Lin, Bei ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN EPIDIDYMIS PROTEIN 4; PROTEIN; TUMOR MARKER; WFDC2 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CLEAR CELL CARCINOMA; COLLOID CARCINOMA; ENDOMETRIUM; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; UNDIFFERENTIATED CARCINOMA; AGED; BIOSYNTHESIS; ENDOMETRIUM TUMOR; GENE EXPRESSION REGULATION; GENETICS; HYPERPLASIA; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; BIOMARKERS, TUMOR; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERPLASIA; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTEINS;

EID: 84945951371     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2018/6795629     Document Type: Erratum

References (20)

1. D. J. Brennan, A. Hackethal, A. M. Metcalf et al., "SerumHE4 as a prognosticmarker in endometrial cancer-apopulation based study," Gynecologic Oncology, vol. 132, no. 1, pp. 159-165, 2014.
2. J. Li, S. Dowdy, T. Tipton et al., "HE4 as a biomarker for ovarian and endometrial cancer management," Expert Review of Molecular Diagnostics, vol. 9, no. 6, pp. 555-566, 2009.
3. M. Schummer, W. V. Ng, R. E. Bumgarner et al., "Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas," Gene, vol. 238, no. 2, pp. 375-385, 1999.
4. I. Heliström, J. Raycraft, M. Hayden-Ledbetter et al., "The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma," Cancer Research, vol. 63, no. 13, pp. 3695-3700, 2003.
5. S. K. Saarelainen, N. Peltonen, T. Lehtimäki, A. Perheentupa, M. H. Vuento, and J. U. Mäenpää, "Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma," American Journal of Obstetrics and Gynecology, vol. 209, no. 2, pp. 142. e1-142. e6, 2013.
6. T. van Gorp, I. Cadron, E. Despierre et al., "HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm," British Journal of Cancer, vol. 104, no. 5, pp. 863-870, 2011.
7. K. Tokuishi, S.-I. Yamashita, K. Ohbo, and K. Kawahara, "Splice variant HE4-V3 expression is associated with favorable prognosis in pulmonary adenocarcinoma," Tumor Biology, vol. 33, no. 1, pp. 103-109, 2012.
8. R. L. O'Neal, K. T. Nam, B. J. Lafleur et al., "Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas," Human Pathology, vol. 44, no. 5, pp. 734-742, 2013.
9. C. H. Yang, Y. H. Xu, and X. Y. Zhang, "Expression and significance of human epididymis gene product 4 in tissue and serum of patients with endometrial cancer," Chinese Journal of Clinical Oncology, vol. 38, no. 9, pp. 516-519, 2011.
10. H. Zhuang, J. Gao, Z. Hu, J. Liu, D. Liu, and B. Lin, "Coexpression of Lewis y antigen with human epididymis protein 4 in ovarian epithelial carcinoma," PLoS ONE, vol. 8, no. 7,Article ID e68994, 2013.
11. R. Angioli, F. Plotti, S. Capriglione et al., "Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?" Gynecologic Oncology, vol. 128, no. 3, pp. 579-583, 2013.
12. R. G. Moore, A. K. Brown, M. C. Miller et al., "The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patientswith a pelvic mass," GynecologicOncology, vol. 108, no. 2, pp. 402-408, 2008.
13. R. Angioli, F. Plotti, S. Capriglione et al., "The role of novel biomarker HE4 in endometrial cancer: a case control prospective study," Tumor Biology, vol. 34, no. 1, pp. 571-576, 2013.
14. L. Zanotti, E. Bignotti, S. Calza et al., "Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome," Clinical Chemistry and Laboratory Medicine, vol. 50, no. 12, pp. 2189-2198, 2012.
15. R. G. Moore, C. M. Miller, A. K. Brown, K. Robison, M. Steinhoff, and G. Lambert-Messerlian, "Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus," International Journal of Gynecological Cancer, vol. 21, no. 7, pp. 1185-1190, 2011.
16. J. Li, H. Chen, A. Mariani et al., "HE4 (WFDC2) promotes tumor growth in endometrial cancer cell lines," International Journal ofMolecular Sciences, vol. 14,no. 3, pp. 6026-6043, 2013.
17. J. Watanabe, Y. Kamata, N. Seo, I. Okayasu, and H. Kuramoto, "Stimulatory effect of estrogen on the growth of endometrial cancer cells is regulated by cell-cycle regulators," The Journal of Steroid Biochemistry andMolecular Biology, vol. 107, no. 3-5, pp. 163-171, 2007.
18. E. Bignotti, M. Ragnoli, L. Zanotti et al., "Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients," British Journal of Cancer, vol. 104, no. 9, pp. 1418-1425, 2011.
19. R. Lu, X. Sun,R. Xiao, L. Zhou,X. Gao, and L. Guo, "Humanepididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility," Biochemical and Biophysical Research Communications, vol. 419, no. 2, pp. 274-280, 2012.
20. J.-J. Liu, B. Lin, Y.-Y. Hao et al., "Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway," Oncology Reports, vol. 23, no. 3, pp. 833-841, 2010.